Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.-Reference-Cited by-同舟云学术

Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

Published:2021-08 Issue:8 Volume:53 Page:1011-1019
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Marasco Giovanni,Colecchia Antonio,Bacchi Reggiani Maria Letizia,Celsa Ciro,Farinati Fabio,Giannini Edoardo Giovanni,Benevento Francesca,Rapaccini Gian Ludovico,Caturelli Eugenio,Di Marco Mariella,Biasini Elisabetta,Marra Fabio,Morisco Filomena,Foschi Francesco Giuseppe,Zoli Marco,Gasbarrini Antonio,Baroni Gianluca Svegliati,Masotto Alberto,Sacco Rodolfo,Raimondo Giovanni,Azzaroli Francesco,Mega Andrea,Vidili Gianpaolo,Brunetto Maurizia Rossana,Nardone Gerardo,Dajti Elton,Ravaioli Federico,Avanzato Francesca,Festi Davide,Trevisani Franco

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference48 articles.

1. EASL clinical practice guidelines: management of hepatocellular carcinoma;Galle;J Hepatol,2018

2. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018

3. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med.,2020

4. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017

5. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study;Kelley;Ann Oncol,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conditional survival after radiofrequency ablation for early-stage hepatocellular carcinoma;2024-03-28

2. Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review;Journal of Clinical Medicine Research;2023-04

3. The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab;Journal of Hepatocellular Carcinoma;2022-08

4. Development and External Validation of the Munich Sorafenib Evaluation Score for Hepatocellular Carcinoma;Digestive Diseases;2022-04-14

5. The ITA.LI.CA Consortium: How multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence;Annals of Hepatology;2022-01